
    
      Adult patients with relapsed or refractory CD30-positive Non-Hodgkin Lymphoma who have failed
      standard available therapies and who meet eligibility criteria will have blood drawn to
      manufacture the CD30.CAR-T cells.

      CD30.CAR-T cells will be infused once following the completion of lymphodepleting
      chemotherapy with Bendamustine and Fludarabine.

      Subjects will be closely monitored for DLT and safety.
    
  